In the world of genome sequencing, Illumina (NASDAQ: ILMN) is the undisputed market leader. Pacific Biosciences of California (NASDAQ: PACB) , or PacBio, has been viewed as more of an also-ran since it went public in 2010. Its "long-read" gene sequencing technology was traditionally less accurate than Illumina's competing "short-read" approach, and it comes at a higher cost.
However, after new leadership was brought on and a product update was delivered, its shares have jumped by 700% since the beginning of August.
Is the company finally ready to compete in the growing $5 billion gene sequencing market, or will this hot stock blow up shareholders' portfolios when reality sets in?
For further details see:
Is Pacific Biosciences of California a Ticking Time Bomb for Investors?